Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.

Haddad E, Logan BR, Griffith LM, Buckley RH, Parrott RE, Prockop SE, Small TN, Chaisson J, Dvorak CC, Murnane M, Kapoor N, Abdel-Azim H, Hanson IC, Martinez C, Bleesing JJH, Chandra S, Smith AR, Cavanaugh ME, Jyonouchi S, Sullivan KE, Burroughs L, Skoda-Smith S, Haight AE, Tumlin AG, Quigg TC, Taylor C, Dávila Saldaña BJ, Keller MD, Seroogy CM, Desantes KB, Petrovic A, Leiding JW, Shyr DC, Decaluwe H, Teira P, Gillio AP, Knutsen AP, Moore TB, Kletzel M, Craddock JA, Aquino V, Davis JH, Yu LC, Cuvelier GDE, Bednarski JJ, Goldman FD, Kang EM, Shereck E, Porteus MH, Connelly JA, Fleisher TA, Malech HL, Shearer WT, Szabolcs P, Thakar MS, Vander Lugt MT, Heimall J, Yin Z, Pulsipher MA, Pai SY, Kohn DB, Puck JM, Cowan MJ, O'Reilly RJ, Notarangelo LD.

Blood. 2018 Oct 25;132(17):1737-1749. doi: 10.1182/blood-2018-03-840702. Epub 2018 Aug 28.

2.

Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.

Goldberg JD, Zheng J, Ratan R, Small TN, Lai KC, Boulad F, Castro-Malaspina H, Giralt SA, Jakubowski AA, Kernan NA, O'Reilly RJ, Papadopoulos EB, Young JW, van den Brink MR, Heller G, Perales MA.

Leuk Lymphoma. 2017 Aug;58(8):1859-1871. doi: 10.1080/10428194.2016.1265113. Epub 2017 Jan 10.

3.

Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation.

de la Morena MT, Leonard D, Torgerson TR, Cabral-Marques O, Slatter M, Aghamohammadi A, Chandra S, Murguia-Favela L, Bonilla FA, Kanariou M, Damrongwatanasuk R, Kuo CY, Dvorak CC, Meyts I, Chen K, Kobrynski L, Kapoor N, Richter D, DiGiovanni D, Dhalla F, Farmaki E, Speckmann C, Español T, Shcherbina A, Hanson IC, Litzman J, Routes JM, Wong M, Fuleihan R, Seneviratne SL, Small TN, Janda A, Bezrodnik L, Seger R, Raccio AG, Edgar JD, Chou J, Abbott JK, van Montfrans J, González-Granado LI, Bunin N, Kutukculer N, Gray P, Seminario G, Pasic S, Aquino V, Wysocki C, Abolhassani H, Dorsey M, Cunningham-Rundles C, Knutsen AP, Sleasman J, Costa Carvalho BT, Condino-Neto A, Grunebaum E, Chapel H, Ochs HD, Filipovich A, Cowan M, Gennery A, Cant A, Notarangelo LD, Roifman CM.

J Allergy Clin Immunol. 2017 Apr;139(4):1282-1292. doi: 10.1016/j.jaci.2016.07.039. Epub 2016 Sep 30.

4.

Compound heterozygous mutation of Rag1 leading to Omenn syndrome.

Matthews AG, Briggs CE, Yamanaka K, Small TN, Mooster JL, Bonilla FA, Oettinger MA, Butte MJ.

PLoS One. 2015 Apr 7;10(4):e0121489. doi: 10.1371/journal.pone.0121489. eCollection 2015.

5.

Transplantation outcomes for severe combined immunodeficiency, 2000-2009.

Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Hanson IC, Filipovich AH, Jyonouchi S, Sullivan KE, Small TN, Burroughs L, Skoda-Smith S, Haight AE, Grizzle A, Pulsipher MA, Chan KW, Fuleihan RL, Haddad E, Loechelt B, Aquino VM, Gillio A, Davis J, Knutsen A, Smith AR, Moore TB, Schroeder ML, Goldman FD, Connelly JA, Porteus MH, Xiang Q, Shearer WT, Fleisher TA, Kohn DB, Puck JM, Notarangelo LD, Cowan MJ, O'Reilly RJ.

N Engl J Med. 2014 Jul 31;371(5):434-46. doi: 10.1056/NEJMoa1401177.

6.

Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin.

Olson AL, Dahi PB, Zheng J, Devlin SM, Lubin M, Gonzales AM, Giralt SA, Perales MA, Papadopoulos EB, Ponce DM, Young JW, Kernan NA, Scaradavou A, O'Reilly RJ, Small TN, Papanicolaou G, Barker JN.

Biol Blood Marrow Transplant. 2014 Jun;20(6):787-93. doi: 10.1016/j.bbmt.2014.02.010. Epub 2014 Feb 16.

7.

Primary Immune Deficiency Treatment Consortium (PIDTC) report.

Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Pai SY, Ballard B, Bauer SC, Bleesing JJ, Boyle M, Brower A, Buckley RH, van der Burg M, Burroughs LM, Candotti F, Cant AJ, Chatila T, Cunningham-Rundles C, Dinauer MC, Dvorak CC, Filipovich AH, Fleisher TA, Bobby Gaspar H, Gungor T, Haddad E, Hovermale E, Huang F, Hurley A, Hurley M, Iyengar S, Kang EM, Logan BR, Long-Boyle JR, Malech HL, McGhee SA, Modell F, Modell V, Ochs HD, O'Reilly RJ, Parkman R, Rawlings DJ, Routes JM, Shearer WT, Small TN, Smith H, Sullivan KE, Szabolcs P, Thrasher A, Torgerson TR, Veys P, Weinberg K, Zuniga-Pflucker JC; workshop participants.

J Allergy Clin Immunol. 2014 Feb;133(2):335-47. doi: 10.1016/j.jaci.2013.07.052. Epub 2013 Oct 15.

8.

Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.

Giulino-Roth L, Ricafort R, Kernan NA, Small TN, Trippett TM, Steinherz PG, Prockop SE, Scaradavou A, Chiu M, O'Reilly RJ, Boulad F.

Pediatr Blood Cancer. 2013 Dec;60(12):2018-24. doi: 10.1002/pbc.24722. Epub 2013 Aug 30.

PMID:
24038967
9.

A recessive founder mutation in regulator of telomere elongation helicase 1, RTEL1, underlies severe immunodeficiency and features of Hoyeraal Hreidarsson syndrome.

Ballew BJ, Joseph V, De S, Sarek G, Vannier JB, Stracker T, Schrader KA, Small TN, O'Reilly R, Manschreck C, Harlan Fleischut MM, Zhang L, Sullivan J, Stratton K, Yeager M, Jacobs K, Giri N, Alter BP, Boland J, Burdett L, Offit K, Boulton SJ, Savage SA, Petrini JH.

PLoS Genet. 2013 Aug;9(8):e1003695. doi: 10.1371/journal.pgen.1003695. Epub 2013 Aug 29.

10.

Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.

Ponce DM, Gonzales A, Lubin M, Castro-Malaspina H, Giralt S, Goldberg JD, Hanash AM, Jakubowski A, Jenq R, Papadopoulos EB, Perales MA, van den Brink MR, Young JW, Boulad F, O'Reilly RJ, Prockop S, Small TN, Scaradavou A, Kernan NA, Stevens CE, Barker JN.

Biol Blood Marrow Transplant. 2013 Jun;19(6):904-11. doi: 10.1016/j.bbmt.2013.02.008. Epub 2013 Feb 14.

11.

Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution.

Lee YJ, Chung D, Xiao K, Papadopoulos EB, Barker JN, Small TN, Giralt SA, Zheng J, Jakubowski AA, Papanicolaou GA.

Biol Blood Marrow Transplant. 2013 Mar;19(3):387-92. doi: 10.1016/j.bbmt.2012.10.014. Epub 2012 Oct 22.

12.

Alternative donor SCT for the treatment of MHC class II deficiency.

Small TN, Qasim W, Friedrich W, Chiesa R, Bleesing JJ, Scurlock A, Veys P, Sparber-Sauer M.

Bone Marrow Transplant. 2013 Feb;48(2):226-32. doi: 10.1038/bmt.2012.140. Epub 2012 Sep 24.

PMID:
23000650
13.

Live (vaccines) from New York.

Forlenza CJ, Small TN.

Bone Marrow Transplant. 2013 Jun;48(6):749-54. doi: 10.1038/bmt.2012.141. Epub 2012 Aug 13. Review.

PMID:
22890288
14.

Paroxysmal nocturnal hemoglobinuria in pediatric patients.

Curran KJ, Kernan NA, Prockop SE, Scaradavou A, Small TN, Kobos R, Castro-Malaspina H, Araten D, DiMichele D, O'Reilly RJ, Boulad F.

Pediatr Blood Cancer. 2012 Sep;59(3):525-9. doi: 10.1002/pbc.23410. Epub 2011 Dec 6.

PMID:
22147651
15.

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, Heller G, Barker JN, Boulad F, Castro-Malaspina H, George D, Jakubowski A, Koehne G, Papadopoulos EB, Scaradavou A, Small TN, Khalaf R, Young JW, O'Reilly RJ.

Blood. 2012 Mar 15;119(11):2644-56. doi: 10.1182/blood-2011-08-371971. Epub 2011 Dec 2.

16.

Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.

Kobos R, Steinherz PG, Kernan NA, Prockop SE, Scaradavou A, Small TN, Shukla N, Khalaf R, O'Reilly RJ, Boulad F.

Biol Blood Marrow Transplant. 2012 Mar;18(3):473-80. doi: 10.1016/j.bbmt.2011.11.009. Epub 2011 Nov 10.

17.

Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation.

Mahler MB, Taur Y, Jean R, Kernan NA, Prockop SE, Small TN.

Biol Blood Marrow Transplant. 2012 Jan;18(1):145-9. doi: 10.1016/j.bbmt.2011.07.027. Epub 2011 Aug 4.

18.

T-cell-depleted hematopoietic SCT from unrelated donors for the treatment of congenital amegakaryocytic thrombocytopenia.

Tarek N, Kernan NA, Prockop SE, Scaradavou A, Small TN, O'Reilly RJ, Boulad F.

Bone Marrow Transplant. 2012 May;47(5):744-6. doi: 10.1038/bmt.2011.142. Epub 2011 Jul 25. No abstract available.

PMID:
21785471
19.

Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT).

Chou JF, Kernan NA, Prockop S, Heller G, Scaradavou A, Kobos R, Knowles MA, Papadopoulos EB, Casson A, Copeland C, Torok-Castanza J, Zakak N, Ruggiero J, Small TN.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1708-13. doi: 10.1016/j.bbmt.2011.05.006. Epub 2011 May 23.

20.

Legionella jordanis in hematopoietic SCT patients radiographically mimicking invasive mold infection.

Meyer R, Rappo U, Glickman M, Seo SK, Sepkowitz K, Eagan J, Small TN.

Bone Marrow Transplant. 2011 Aug;46(8):1099-103. doi: 10.1038/bmt.2011.94. Erratum in: Bone Marrow Transplant. 2011 Aug;46(8):1166.

PMID:
21572462
21.

Immunization of hematopoietic stem cell transplant recipients against vaccine-preventable diseases.

Small TN, Cowan MJ.

Expert Rev Clin Immunol. 2011 Mar;7(2):193-203. doi: 10.1586/eci.10.103. Review.

PMID:
21426257
22.

Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin.

Sauter C, Abboud M, Jia X, Heller G, Gonzales AM, Lubin M, Hawke R, Perales MA, van den Brink MR, Giralt S, Papanicolaou G, Scaradavou A, Small TN, Barker JN.

Biol Blood Marrow Transplant. 2011 Oct;17(10):1460-71. doi: 10.1016/j.bbmt.2011.02.001. Epub 2011 Mar 1.

23.

T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies.

Jakubowski AA, Small TN, Kernan NA, Castro-Malaspina H, Collins N, Koehne G, Hsu KC, Perales MA, Papanicolaou G, van den Brink MR, O'Reilly RJ, Young JW, Papadopoulos EB.

Biol Blood Marrow Transplant. 2011 Sep;17(9):1335-42. doi: 10.1016/j.bbmt.2011.01.005. Epub 2011 Jan 11.

24.

Vaccination of SCT recipients.

Ljungman P, Small TN; Vaccination Recommendations Writing Group.

Bone Marrow Transplant. 2011 Apr;46(4):621. doi: 10.1038/bmt.2010.274. Epub 2010 Nov 22. No abstract available.

PMID:
21102502
25.

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.

Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL, Maziarz RT, Stadtmauer EA, Bolaños-Meade J, Brown J, Dipersio JF, Boeckh M, Marr KA; Blood and Marrow Transplant Clinical Trials Network.

Blood. 2010 Dec 9;116(24):5111-8. doi: 10.1182/blood-2010-02-268151. Epub 2010 Sep 8.

26.

Update to vaccination guidelines.

Ljungman P, Small TN; vaccination recommendations writing group.

Biol Blood Marrow Transplant. 2010 Nov;16(11):1608-9. doi: 10.1016/j.bbmt.2010.08.009. Epub 2010 Aug 21. No abstract available.

27.

Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT.

Perales MA, Jenq R, Goldberg JD, Wilton AS, Lee SS, Castro-Malaspina HR, Hsu K, Papadopoulos EB, van den Brink MR, Boulad F, Kernan NA, Small TN, Wolden S, Collins NH, Chiu M, Heller G, O'Reilly RJ, Kewalramani T, Young JW, Jakubowski AA.

Bone Marrow Transplant. 2010 Sep;45(9):1408-16. doi: 10.1038/bmt.2009.371. Epub 2010 Jan 11.

28.

Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.

Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, Fleisher TA, Gaspar HB, Kohn DB, Ochs HD, O'Reilly RJ, Rizzo JD, Roifman CM, Small TN, Shearer WT; Workshop Participants.

J Allergy Clin Immunol. 2009 Dec;124(6):1152-60.e12. doi: 10.1016/j.jaci.2009.10.022.

29.

Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation.

Small TN, Zelenetz AD, Noy A, Rice RD, Trippett TM, Abrey L, Portlock CS, McCullagh EJ, Vanak JM, Mulligan AM, Moskowitz CH.

Biol Blood Marrow Transplant. 2009 Dec;15(12):1538-42. doi: 10.1016/j.bbmt.2009.07.018. Epub 2009 Sep 25.

30.

Comparison of immune recovery in recipients of unmanipulated vs T-cell-depleted grafts from unrelated donors in a multicenter randomized phase II-III trial (T-cell depletion trial).

Keever-Taylor CA, Wagner JE, Kernan NA, Small TN, Carter SL, Thompson JS, Cloud GA, Lamb LS.

Bone Marrow Transplant. 2010 Mar;45(3):587-9. doi: 10.1038/bmt.2009.170. Epub 2009 Jul 20. No abstract available.

31.

B cells and transplantation: an educational resource.

Small TN, Robinson WH, Miklos DB.

Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):104-13. doi: 10.1016/j.bbmt.2008.10.016. Review. No abstract available. Erratum in: Biol Blood Marrow Transplant. 2009 Aug;15(8):1003.

32.

Vancomycin-resistant enterococcus in pediatric oncology patients: An analysis of potential consequences of colonization and infection.

Kosack A, Riedel E, Kiehn TE, Small TN, Wexler LH, Dunkel IJ.

Pediatr Blood Cancer. 2009 Feb;52(2):300-2. doi: 10.1002/pbc.21793.

PMID:
18837434
33.

Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT).

Pao M, Papadopoulos EB, Chou J, Glenn H, Castro-Malaspina H, Jakubowski AA, Kernan NA, Perales MA, Prokop S, Scaradavou A, vanDenBrink MR, Young JW, O'Reilly RJ, Small TN.

Biol Blood Marrow Transplant. 2008 Sep;14(9):1022-1030. doi: 10.1016/j.bbmt.2008.06.012. Erratum in: Biol Blood Marrow Transplant. 2008 Nov;14(11):1319.

34.

Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.

Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, Boulad F, Young JW, Kernan NA, Perales MA, Small TN, Hsu K, Chiu M, Heller G, Collins NH, Jhanwar SC, van den Brink M, Nimer SD, O'Reilly RJ.

Biol Blood Marrow Transplant. 2008 Apr;14(4):458-68. doi: 10.1016/j.bbmt.2008.02.006.

35.

Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.

Chaudhury S, Auerbach AD, Kernan NA, Small TN, Prockop SE, Scaradavou A, Heller G, Wolden S, O'Reilly RJ, Boulad F.

Br J Haematol. 2008 Mar;140(6):644-55. doi: 10.1111/j.1365-2141.2007.06975.x. Review.

PMID:
18302713
36.

Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.

Chewning JH, Castro-Malaspina H, Jakubowski A, Kernan NA, Papadopoulos EB, Small TN, Heller G, Hsu KC, Perales MA, van den Brink MR, Young JW, Prockop SE, Collins NH, O'Reilly RJ, Boulad F.

Biol Blood Marrow Transplant. 2007 Nov;13(11):1313-23. Epub 2007 Sep 7.

37.

T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin.

Jakubowski AA, Small TN, Young JW, Kernan NA, Castro-Malaspina H, Hsu KC, Perales MA, Collins N, Cisek C, Chiu M, van den Brink MR, O'Reilly RJ, Papadopoulos EB.

Blood. 2007 Dec 15;110(13):4552-9. Epub 2007 Aug 23.

38.

Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease.

Perales MA, Ishill N, Lomazow WA, Weinstock DM, Papadopoulos EB, Dastigir H, Chiu M, Boulad F, Castro-Malaspina HR, Heller G, Jakubowski AA, O'Reilly RJ, Small TN, Young JW, Kernan NA.

Bone Marrow Transplant. 2007 Sep;40(5):481-6. Epub 2007 Jul 9.

PMID:
17618322
39.

Final height in pediatric patients after hyperfractionated total body irradiation and stem cell transplantation.

Chemaitilly W, Boulad F, Heller G, Kernan NA, Small TN, O'Reilly RJ, Sklar CA.

Bone Marrow Transplant. 2007 Jul;40(1):29-35. Epub 2007 Apr 30.

PMID:
17468769
40.

Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.

Small TN, Young JW, Castro-Malaspina H, Prockop S, Wilton A, Heller G, Boulad F, Chiu M, Hsu K, Jakubowski A, Kernan NA, Perales MA, O'Reilly RJ, Papadopoulos EB.

Biol Blood Marrow Transplant. 2007 Feb;13(2):235-44.

41.

Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants.

Jaffe D, Papadopoulos EB, Young JW, O'reilly RJ, Prockop S, Kernan NA, Jakubowski A, Boulad F, Perales MA, Castro-Malaspina H, Small TN.

Blood. 2006 Oct 1;108(7):2470-5. Epub 2006 Jun 8.

42.

Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients.

Almyroudis NG, Fuller A, Jakubowski A, Sepkowitz K, Jaffe D, Small TN, Kiehn TE, Pamer E, Papanicolaou GA.

Transpl Infect Dis. 2005 Mar;7(1):11-7.

PMID:
15984943
43.

Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations.

Lewin SR, Heller G, Zhang L, Rodrigues E, Skulsky E, van den Brink MR, Small TN, Kernan NA, O'Reilly RJ, Ho DD, Young JW.

Blood. 2002 Sep 15;100(6):2235-42.

PMID:
12200390
44.

Safe and cost effective use of alteplase for the clearance of occluded central venous access devices.

Timoney JP, Malkin MG, Leone DM, Groeger JS, Heaney ML, Keefe DL, Klang M, Lucarelli CD, Muller RJ, Eng SL, Connor M, Small TN, Brown AE, Saltz LB.

J Clin Oncol. 2002 Apr 1;20(7):1918-22.

PMID:
11919252
45.

Respiratory syncytial virus infection following hematopoietic stem cell transplantation.

Small TN, Casson A, Malak SF, Boulad F, Kiehn TE, Stiles J, Ushay HM, Sepkowitz KA.

Bone Marrow Transplant. 2002 Feb;29(4):321-7.

46.

Lung transplantation after allogeneic marrow transplantation in pediatric patients: the Memorial Sloan-Kettering experience.

Heath JA, Kurland G, Spray TL, Kernan NA, Small TN, Brochstein JA, Gillio AP, Boklan J, O'Reilly RJ, Boulad F.

Transplantation. 2001 Dec 27;72(12):1986-90.

PMID:
11773900
47.

Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts.

Boulad F, Gillio A, Small TN, George D, Prasad V, Torok-Castanza J, Regan AD, Collins N, Auerbach AD, Kernan NA, O'Reilly RJ.

Br J Haematol. 2000 Dec;111(4):1153-7.

PMID:
11167755
48.

Disseminated toxoplasmosis following T cell-depleted related and unrelated bone marrow transplantation.

Small TN, Leung L, Stiles J, Kiehn TE, Malak SA, O'Reilly RJ, Sepkowitz K.

Bone Marrow Transplant. 2000 May;25(9):969-73.

49.

Association of reticular dysgenesis (thymic alymphoplasia and congenital aleukocytosis) with bilateral sensorineural deafness.

Small TN, Wall DA, Kurtzberg J, Cowan MJ, O'Reilly RJ, Friedrich W.

J Pediatr. 1999 Sep;135(3):387-9.

PMID:
10484810
50.

Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study.

Boulad F, Steinherz P, Reyes B, Heller G, Gillio AP, Small TN, Brochstein JA, Kernan NA, O'Reilly RJ.

J Clin Oncol. 1999 Jan;17(1):197-207.

PMID:
10458234

Supplemental Content

Loading ...
Support Center